Postoperative hypoxemia, postoperative respiratory infection
Conditions
Interventions
Penehyclidine bolus group:Preoperative bolus injection of 0.5 mg penehyclidine hydrochloride
Penehyclidine infusion group:0.25 mg of penehyclidine hydrochloride will be injected before surgery and 0.25 mg of penehyclidine hydrochloride will be injected into the intravenous analgesia pump afte
Control group:No perioperative use of penehyclidine
Sponsors
Shanxi Province Cancer Hospital
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Patients with a clear diagnosis of non-small cell lung cancer by preoperative pathology; 2) Patients with chest CT tumors confined to a single lobe of the lung before surgery, without invading the main bronchus, etc., and without distant metastasis; 3) Patient age >50 years old; 4) Duration >2h; 5) Patients with high risk of postoperative pulmonary complications which means ARISCAT score =45 points; 6) ASA score ?~?; 7) Voluntary signing of informed consent.
Exclusion criteria
Exclusion criteria: 1) Other types of lung cancer, or patients who do not meet the indications for VATS surgery (including those who are converted to thoracotomy) 2) Patients who are allergic to atropine, scopolamine or other anticholinergic drugs 3) Patients with a history of moderate to severe prostatic hypertrophy or glaucoma; 4) Patients who have inhaled ß2 receptor agonists, M receptor blockers and/or glucocorticoids within 1 month before surgery; 5) Patients with a history of stroke within 3 months; 6) Patients with a history of myocardial infarction, severe heart failure (New York Heart Association heart function grade higher than grade 3) or rapid arrhythmia within 1 year; 7) History of schizophrenia, Parkinson's disease or severe dementia or language disorders 8) Severe liver dysfunction (Child-Pugh C grade); severe renal insufficiency (needing renal replacement therapy) or) ASA grade = IV or expected survival = 24h; 9) Participated in other drug clinical studies within 1 month before surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arterial oxygen saturation;Postoperative Inflammatory pulmonary lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Peak airway pressure;Arterial oxygen tension;Postoperative Pulmonary and respiratory tract infections (bacteremia, urinary tract infection, incision infection);Postoperative pneumothorax;Postoperative VAS pain score;Postoperative Delirium;Postoperative nausea and vomiting;Number of days chest tube was indwelling;Postoperative hospital stay; | — |
Countries
China
Contacts
Public ContactShouyuan Tian
Shanxi Province Cancer Hospital
Outcome results
None listed